Health & Pharma
Cerebras accelerates AI to drive faster drug discovery and enable more accurate healthcare recommendations based on vastly larger datasets.
AI has industry-changing potential to accelerate biomedical research and drug discovery, and improve data-driven healthcare recommendations.
But these complex problems need large, complex models to represent them, and datasets in this space are enormous. These experiments today take too long to train and are too slow in inference. Traditional hardware limits how quickly researchers can innovate and constrains the image resolution and sequence lengths they can use.
CS-2 offers cluster-scale AI acceleration in a single, easy-to-program device, so your researchers can focus on medical innovation; not on overcoming speed and scaling challenges.
Traditional laboratory based drug screening is a slow process, taking years for a compound to progress from research into trials. AI models like Transformers, Graph Neural Networks (GNNs), and Multi-Layer Perceptrons (MLPs) use complex software to screen large libraries of candidate drug molecules; selecting only the most promising ones for subsequent trials. Using computers instead of laboratories enables faster screening and advances the most promising candidate compounds more quickly, dramatically reducing drug development time. Deep neural networks have shown exceptional results, and are now considered among the most powerful computational tools for virtual drug screening.
In partnership with customers, the CS-2 system has demonstrated vast improvements in deep neural network-based virtual screening – in one case reducing screening time for a large library of compounds from 183 days on a GPU cluster to 3.5 days on the CS-2. This 50 X acceleration means reducing time to solution by six months. Faster time to solution reduces time to cure.
SVP Global Head of AI and ML @ GlaxoSmithKline
Text and language modeling
Neural networks like BERT and GPT can model semantic relationships within records, reports, and scientific literature, so you can instantly answer questions using this database of knowledge.
Today, the compute resources and expertise needed to efficiently work with large language models – such as BERT and GPT – and massive real-world text databases are only available in hyperscale datacenters. With a single CS-2, your organization can train models like these in hours or days rather than weeks or months.
Genomics and data science
In genomics, AI has shown great potential for identifying subtle signatures of public health challenges as well as new opportunities for the treatment of rare diseases.
However, most work in this space has been limited to small clinical trials or local populations because the deep learning models used to classify sequences or predict phenotype — e.g. RNNs, Transformers, 1D CNNs — take too long to train or process with large, sparse datasets on GPU. Use the CS-2 to bring 100x – 1,000x more data to your models.
Care and treatment analytics
Knowledge graphs and graph neural networks can be used to represent the complex landscape of patients – treatments, outcomes, costs – and to recommend better data-driven courses of care.
While this potential is great, the inputs are enormous — large, sparse datasets of health records and reports, and massive patient population graphs.
With 850,000 cores, 40 GB of fast on-wafer SRAM memory, and a super-fast on-wafer communication fabric, Cerebras’ WSE-2 supports larger graphs at orders of magnitude greater performance and efficiency than a cluster of traditional machines.